1.
Evid. actual. práct. ambul
;
20(2): 41-41, 2017. tab
Artículo
en Español
| LILACS
| ID: biblio-1128707
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Quinolonas/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Combinación Fluticasona-Salmeterol/uso terapéutico , Glucocorticoides/uso terapéutico , Glicopirrolato/uso terapéutico , Indanos/uso terapéutico , Administración por Inhalación , Ensayos Clínicos Controlados Aleatorios como Asunto , Quinolonas/efectos adversos , Antagonistas Muscarínicos/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Combinación de Medicamentos , Combinación Fluticasona-Salmeterol/efectos adversos , Glicopirrolato/efectos adversos , Indanos/efectos adversos
2.
Indian J Exp Biol
;
1992 Jul; 30(7): 583-6
Artículo
en Inglés
| IMSEAR
| ID: sea-56077
RESUMEN
In line of the effort towards development of some newer indanyl non-steroidal anti-inflammatory agents and providing comprehensive SAR among this class of compounds some significantly active derivatives with low ulcerogenic potential were identified. Dealing with various long chain and branched chain compounds among this series, 3-(5, 6-dimethoxy indan-1-yl) propionic acid, 2-(5, 6-dimethoxy indan-1-yl) propionic acid and 3-(6-methoxy indan-1-yl) propionic acid were observed to have encouraging biological activity. Screening in various animal models of inflammation suggests their longer duration of action and lower ulcerogenic liability.